Call for Elan to publish Alzheimer's trial details


One potential route for therapy for Alzheimer's disease involves the immunization of patients against the amyloid-β peptide, the major proteinaceous component that characterizes plaques in the brains of patients with this disease. Resulting from earlier research on mice, published in Nature1,2,3, Elan Pharmaceuticals recently began clinical trials of a vaccine, AN-1792, based on this approach. In January, four patients in this trial developed inflammation of the central nervous system, and Elan suspended the trial pending further investigation4. By March, the number of patients in this trial who had symptoms resembling encephalitis and meningitis was reported to have increased to 15, and Elan has permanently withdrawn the AN-1792 vaccine from human trials5.

It is not clear precisely what caused the inflammation in these patients, as Elan has released few details of their medical condition. Elan is under no obligation to report the results of the AN-1792 trials, and may well not wish to lose its perceived scientific or commercial advantage.

Nonetheless, detailed information of the conditions developed by these patients is of profound interest to the scientific community as well as society at large. We therefore urge Elan to publish details from their study as quickly as possible, so that any foreseeable side-effects can be avoided in future trials.


  1. 1

    Schenk, D. et al. Nature 400, 173–177 (1999).

  2. 2

    Janus, C. et al. Nature 408, 979–982 (2000).

  3. 3

    Morgan, D. et al. Nature 408, 982–985 (2000).

  4. 4

    Check, E. Nature 415, 462 (2002).

  5. 5

    Weiss, R. Washington Post A03 (2 March 2002)

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.